CombiGene AB (publ) (COMBI.ST)
SEK 2.7
(-0.74%)
SEK 2.7
(-0.74%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | -1.79 Million SEK | -179900100.0% |
| 2022 | 1.00 SEK | 0.0% |
| 2021 | - SEK | -100.0% |
| 2020 | 823.79 Thousand SEK | -58.81% |
| 2019 | 2 Million SEK | 271.1% |
| 2018 | -1.16 Million SEK | 22.07% |
| 2017 | -1.5 Million SEK | -221.61% |
| 2016 | -466.4 Thousand SEK | 0.0% |
| 2015 | - SEK | 0.0% |
| 2014 | - SEK | 0.0% |
| 2013 | - SEK | 0.0% |
| 2012 | - SEK | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | -1.11 Million SEK | 0.0% |
| 2024 Q1 | - SEK | 100.0% |
| 2023 Q3 | 1.00 SEK | 0.0% |
| 2023 Q2 | - SEK | 0.0% |
| 2023 Q4 | -1.79 Million SEK | -179900100.0% |
| 2023 FY | -1.79 Million SEK | -179900100.0% |
| 2023 Q1 | - SEK | -100.0% |
| 2022 Q2 | 7.25 Million SEK | -44.67% |
| 2022 Q3 | -5.6 Million SEK | -177.29% |
| 2022 Q4 | 1.00 SEK | 100.0% |
| 2022 FY | 1.00 SEK | 0.0% |
| 2022 Q1 | 13.11 Million SEK | 275.7% |
| 2021 FY | - SEK | -100.0% |
| 2021 Q4 | -7.46 Million SEK | -1005.82% |
| 2021 Q3 | 824 Thousand SEK | 0.0% |
| 2021 Q2 | 824 Thousand SEK | 0.0% |
| 2021 Q1 | 824 Thousand SEK | 0.02% |
| 2020 FY | 823.79 Thousand SEK | -58.81% |
| 2020 Q3 | 1.64 Million SEK | 0.0% |
| 2020 Q2 | - SEK | 0.0% |
| 2020 Q4 | 823.79 Thousand SEK | -50.01% |
| 2020 Q1 | - SEK | 0.0% |
| 2019 Q4 | - SEK | 0.0% |
| 2019 FY | 2 Million SEK | 271.1% |
| 2019 Q2 | - SEK | 0.0% |
| 2019 Q3 | - SEK | 0.0% |
| 2019 Q1 | - SEK | 0.0% |
| 2018 Q1 | - SEK | 100.0% |
| 2018 Q2 | - SEK | 0.0% |
| 2018 Q4 | - SEK | 0.0% |
| 2018 FY | -1.16 Million SEK | 22.07% |
| 2018 Q3 | - SEK | 0.0% |
| 2017 Q1 | - SEK | 0.0% |
| 2017 Q3 | - SEK | 0.0% |
| 2017 Q4 | -1.5 Million SEK | 0.0% |
| 2017 FY | -1.5 Million SEK | -221.61% |
| 2017 Q2 | - SEK | 0.0% |
| 2016 FY | -466.4 Thousand SEK | 0.0% |
| 2016 Q3 | - SEK | 0.0% |
| 2016 Q1 | - SEK | 0.0% |
| 2016 Q4 | - SEK | 0.0% |
| 2016 Q2 | - SEK | 0.0% |
| 2015 Q4 | - SEK | 0.0% |
| 2015 Q2 | - SEK | 0.0% |
| 2015 Q1 | - SEK | 0.0% |
| 2015 FY | - SEK | 0.0% |
| 2015 Q3 | - SEK | 0.0% |
| 2014 Q4 | - SEK | 0.0% |
| 2014 FY | - SEK | 0.0% |
| 2014 Q1 | - SEK | 0.0% |
| 2013 FY | - SEK | 0.0% |
| 2012 FY | - SEK | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 2.00 SEK | 89950100.0% |
| Ziccum AB (publ) | -4.18 Million SEK | 57.054% |
| Modus Therapeutics Holding AB (publ) | - SEK | Infinity% |
| BioArctic AB (publ) | - SEK | Infinity% |
| Sprint Bioscience AB (publ) | -7.13 Million SEK | 74.79% |
| Mendus AB (publ) | - SEK | Infinity% |
| Genovis AB (publ.) | 14.9 Million SEK | 112.07% |
| Intervacc AB (publ) | 10.48 Million SEK | 117.161% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | - SEK | Infinity% |
| Active Biotech AB (publ) | -2500.00 SEK | -71860.0% |
| Magle Chemoswed Holding AB (publ) | 35.22 Million SEK | 105.107% |
| Bio-Works Technologies AB (publ) | 9.06 Million SEK | 119.839% |
| Aptahem AB (publ) | - SEK | Infinity% |
| Vicore Pharma Holding AB (publ) | - SEK | Infinity% |
| Kancera AB (publ) | -1950.00 SEK | -92156.41% |
| Infant Bacterial Therapeutics AB (publ) | - SEK | Infinity% |
| Fluicell AB (publ) | 3.15 Million SEK | 157.111% |
| Saniona AB (publ) | 1.00 SEK | 179900100.0% |
| Lipigon Pharmaceuticals AB (publ) | -1.62 Million SEK | -10.64% |
| Biovica International AB (publ) | 2.19 Million SEK | 181.81% |
| Spago Nanomedical AB (publ) | 1.00 SEK | 179900100.0% |
| AcouSort AB (publ) | 2.08 Million SEK | 186.49% |
| Xintela AB (publ) | 398 Thousand SEK | 552.01% |
| Abliva AB (publ) | - SEK | Infinity% |
| Egetis Therapeutics AB (publ) | 700 Thousand SEK | 357.0% |
| Karolinska Development AB (publ) | - SEK | Infinity% |
| OncoZenge AB (publ) | -862.99 Thousand SEK | -108.459% |
| Amniotics AB (publ) | 534 Thousand SEK | 436.891% |
| 2cureX AB (publ) | -1000.00 SEK | -179800.0% |
| Asarina Pharma AB (publ) | - SEK | Infinity% |
| Calliditas Therapeutics AB (publ) | 20.42 Million SEK | 108.807% |
| Camurus AB (publ) | 100.95 Million SEK | 101.782% |
| Corline Biomedical AB | -3.85 Million SEK | 53.358% |
| IRLAB Therapeutics AB (publ) | 1000.00 SEK | 180000.0% |
| Isofol Medical AB (publ) | - SEK | Infinity% |
| I-Tech AB | 4.28 Million SEK | 142.033% |
| Hansa Biopharma AB (publ) | 9.79 Million SEK | 118.372% |
| Cyxone AB (publ) | - SEK | Infinity% |
| ExpreS2ion Biotech Holding AB (publ) | - SEK | Infinity% |
| Biosergen AB | -4.92 Million SEK | 63.502% |
| Cantargia AB (publ) | - SEK | Infinity% |
| NextCell Pharma AB | 545.23 Thousand SEK | 429.948% |
| Xspray Pharma AB (publ) | 43.78 Million SEK | 104.109% |
| Elicera Therapeutics AB (publ) | -446.98 Thousand SEK | -302.473% |
| Nanologica AB (publ) | 2.97 Million SEK | 160.511% |
| SynAct Pharma AB | - SEK | Infinity% |
| Annexin Pharmaceuticals AB (publ) | - SEK | Infinity% |
| Stayble Therapeutics AB (publ) | -321.14 Thousand SEK | -460.183% |
| LIDDS AB (publ) | - SEK | Infinity% |
| Lipum AB (publ) | - SEK | Infinity% |
| BioInvent International AB (publ) | 11.84 Million SEK | 115.189% |
| Alzinova AB (publ) | -3.27 Million SEK | 45.119% |
| Oncopeptides AB (publ) | 2.42 Million SEK | 174.186% |
| Pila Pharma AB (publ) | 1.00 SEK | 179900100.0% |
| Guard Therapeutics International AB (publ) | -1486.00 SEK | -120963.257% |
| Scandinavian ChemoTech AB (publ) | 4.03 Million SEK | 144.596% |
| Simris Alg AB (publ) | 1.09 Million SEK | 264.895% |
| Diamyd Medical AB (publ) | 24.05 Million SEK | 107.48% |
| Xbrane Biopharma AB (publ) | 106.85 Million SEK | 101.684% |
| Ascelia Pharma AB (publ) | - SEK | Infinity% |
| Diagonal Bio AB (publ) | 1.02 Million SEK | 275.0% |